Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide

Simes, Bryce C, MacGregor, Gordon G·2019·Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
DOI 10.2147/dmso.s212003

Cited by (104)

Items 101–104 of 104

  1. Sodium-Glucose Cotransporter-2 Inhibitors Following Acute Myocardial Infarction in Patients Without Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
    Muhammad Ahmed, Muhammad Hamza Shuja, Shajia Shakil, Huzaifa Ul Haq Ansari, Firzah Shakil, Muhammad Abdullah Naveed, Syed Atta Ur Rehman, Narmeen Shaikh, Syed Hassaan Ali, Haya Waseem Ansari et al. · 2026 · Clinical Medicine Insights Cardiology
  2. SGLT2i NEUROPROTECTIVE PROPERTIES IN DEPRESSION, AUTISM SPECTRUM DISORDER AND EPILEPSY
    Dominik Zając, Dominika Darasz, Jakub Jucha, Izabela Ochońska, Oliwia Dziewięcka, Wojciech Ziębka, Michał Żołyński, Marta Kaczorek, Krzysztof Machnik, Marek Łobaziewicz · 2026 · International Journal of Innovative Technologies in Social Science
  3. Metabolic and neuropathic outcomes following combined sodium-glucose cotransporter-2 inhibitor therapy and adjunctive acupuncture in obese patients with diabetic neuropathy: a case series
    Yun Jin Kim · 2026 · Frontiers in Pain Research
  4. The Aging Brain and Epilepsy: Current Knowledge and Novel Therapeutic Targets
    Wolfgang Löscher, Patrick Alexander Forcelli · 2026 · Pharmacological Reviews